APO Research
Talk to an analyst

APO RESEARCH · REPORT

Latanoprost for Chronic Angle Closure Glaucoma

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Latanoprost for Chronic Angle Closure Glaucoma Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

29 December 2025183 pages

Choose your research edition.

Industry ResearchLatanoprost for Chronic Angle Closure Glaucoma Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Latanoprost for Chronic Angle Closure Glaucoma Industry Growth and Trends Forecast to 203295 pages · $3,450 USDMarket StructureGlobal Latanoprost for Chronic Angle Closure Glaucoma Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032183 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Latanoprost for Chronic Angle Closure Glaucoma Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Latanoprost for Chronic Angle Closure Glaucoma Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Latanoprost for Chronic Angle Closure Glaucoma market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Latanoprost for Chronic Angle Closure Glaucoma is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Latanoprost for Chronic Angle Closure Glaucoma is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Latanoprost for Chronic Angle Closure Glaucoma is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Latanoprost for Chronic Angle Closure Glaucoma is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Latanoprost for Chronic Angle Closure Glaucoma include CR Zizhu, Novartis, Mylan, China Medical System Holdings, Pfizer, Jiangsu Hengrui Pharmaceuticals, Teva, Taj Pharma and Apotex, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Latanoprost for Chronic Angle Closure Glaucoma market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Latanoprost for Chronic Angle Closure Glaucoma and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Latanoprost for Chronic Angle Closure Glaucoma sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Latanoprost for Chronic Angle Closure Glaucoma market size, projected growth trends, production technologies, key applications, and end-use industries.

Latanoprost for Chronic Angle Closure Glaucoma Segment by Company

CR Zizhu

Novartis

Mylan

China Medical System Holdings

Pfizer

Jiangsu Hengrui Pharmaceuticals

Teva

Taj Pharma

Apotex

Latanoprost for Chronic Angle Closure Glaucoma Segment by Type

Brand Drug

Generic Drug

Latanoprost for Chronic Angle Closure Glaucoma Segment by Application

Male Patients

Female Patients

Latanoprost for Chronic Angle Closure Glaucoma Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Latanoprost for Chronic Angle Closure Glaucoma market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Latanoprost for Chronic Angle Closure Glaucoma and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Latanoprost for Chronic Angle Closure Glaucoma.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Latanoprost for Chronic Angle Closure Glaucoma market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Latanoprost for Chronic Angle Closure Glaucoma manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Latanoprost for Chronic Angle Closure Glaucoma in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Latanoprost for Chronic Angle Closure Glaucoma in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Latanoprost for Chronic Angle Closure Glaucoma Industry Trends Table 2. Latanoprost for Chronic Angle Closure Glaucoma Industry Drivers Table 3. Latanoprost for Chronic Angle Closure Glaucoma Industry Opportunities and Challenges Table 4. Latanoprost for Chronic Angle Closure Glaucoma Industry Restraints Table 5. Global Latanoprost for Chronic Angle Closure Glaucoma Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Latanoprost for Chronic Angle Closure Glaucoma Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Latanoprost for Chronic Angle Closure Glaucoma Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Latanoprost for Chronic Angle Closure Glaucoma Sales Market Share by Manufacturers Table 9. Global Latanoprost for Chronic Angle Closure Glaucoma Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Latanoprost for Chronic Angle Closure Glaucoma Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Latanoprost for Chronic Angle Closure Glaucoma Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Latanoprost for Chronic Angle Closure Glaucoma Manufacturers, Product Type & Application Table 13. Global Latanoprost for Chronic Angle Closure Glaucoma Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Latanoprost for Chronic Angle Closure Glaucoma by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Brand Drug Table 17. Major Manufacturers of Generic Drug Table 18. Global Latanoprost for Chronic Angle Closure Glaucoma Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 19. Global Latanoprost for Chronic Angle Closure Glaucoma Sales by Type (2021-2026) & (K Units) Table 20. Global Latanoprost for Chronic Angle Closure Glaucoma Sales by Type (2027-2032) & (K Units) Table 21. Global Latanoprost for Chronic Angle Closure Glaucoma Sales Market Share by Type (2021-2026) Table 22. Global Latanoprost for Chronic Angle Closure Glaucoma Sales Market Share by Type (2027-2032) Table 23. Global Latanoprost for Chronic Angle Closure Glaucoma Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Latanoprost for Chronic Angle Closure Glaucoma Revenue by Type (2021-2026) & (K Units) Table 25. Global Latanoprost for Chronic Angle Closure Glaucoma Revenue by Type (2027-2032) & (K Units) Table 26. Global Latanoprost for Chronic Angle Closure Glaucoma Revenue Market Share by Type (2021-2026) Table 27. Global Latanoprost for Chronic Angle Closure Glaucoma Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Male Patients Table 29. Major Manufacturers of Female Patients Table 30. Global Latanoprost for Chronic Angle Closure Glaucoma Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 31. Global Latanoprost for Chronic Angle Closure Glaucoma Sales by Application (2021-2026) & (K Units) Table 32. Global Latanoprost for Chronic Angle Closure Glaucoma Sales by Application (2027-2032) & (K Units) Table 33. Global Latanoprost for Chronic Angle Closure Glaucoma Sales Market Share by Application (2021-2026) Table 34. Global Latanoprost for Chronic Angle Closure Glaucoma Sales Market Share by Application (2027-2032) Table 35. Global Latanoprost for Chronic Angle Closure Glaucoma Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global Latanoprost for Chronic Angle Closure Glaucoma Revenue by Application (2021-2026) & (K Units) Table 37. Global Latanoprost for Chronic Angle Closure Glaucoma Revenue by Application (2027-2032) & (K Units) Table 38. Global Latanoprost for Chronic Angle Closure Glaucoma Revenue Market Share by Application (2021-2026) Table 39. Global Latanoprost for Chronic Angle Closure Glaucoma Revenue Market Share by Application (2027-2032) Table 40. Global Latanoprost for Chronic Angle Closure Glaucoma Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 41. Global Latanoprost for Chronic Angle Closure Glaucoma Sales by Region (2021-2026) & (K Units) Table 42. Global Latanoprost for Chronic Angle Closure Glaucoma Sales Market Share by Region (2021-2026) Table 43. Global Latanoprost for Chronic Angle Closure Glaucoma Sales Forecasted by Region (2027-2032) & (K Units) Table 44. Global Latanoprost for Chronic Angle Closure Glaucoma Sales Forecasted Market Share by Region (2027-2032) Table 45. North America Latanoprost for Chronic Angle Closure Glaucoma Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 46. North America Latanoprost for Chronic Angle Closure Glaucoma Sales by Country (2021-2026) & (K Units) Table 47. North America Latanoprost for Chronic Angle Closure Glaucoma Sales by Country (2027-2032) & (K Units) Table 48. Europe Latanoprost for Chronic Angle Closure Glaucoma Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 49. Europe Latanoprost for Chronic Angle Closure Glaucoma Sales by Country (2021-2026) & (K Units) Table 50. Europe Latanoprost for Chronic Angle Closure Glaucoma Sales by Country (2027-2032) & (K Units) Table 51. Asia Pacific Latanoprost for Chronic Angle Closure Glaucoma Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 52. Asia Pacific Latanoprost for Chronic Angle Closure Glaucoma Sales by Country (2021-2026) & (K Units) Table 53. Asia Pacific Latanoprost for Chronic Angle Closure Glaucoma Sales by Country (2027-2032) & (K Units) Table 54. South America, Middle East and Africa Latanoprost for Chronic Angle Closure Glaucoma Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. South America, Middle East and Africa Latanoprost for Chronic Angle Closure Glaucoma Sales by Country (2021-2026) & (K Units) Table 56. South America, Middle East and Africa Latanoprost for Chronic Angle Closure Glaucoma Sales by Country (2027-2032) & (K Units) Table 57. Global Latanoprost for Chronic Angle Closure Glaucoma Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Latanoprost for Chronic Angle Closure Glaucoma Revenue by Region (2021-2026) & (US$ Million) Table 59. Global Latanoprost for Chronic Angle Closure Glaucoma Revenue by Region (2027-2032) & (US$ Million) Table 60. Global Latanoprost for Chronic Angle Closure Glaucoma Revenue Market Share by Region (2021-2026) Table 61. Global Latanoprost for Chronic Angle Closure Glaucoma Revenue Market Share by Region (2027-2032) Table 62. CR Zizhu Company Information Table 63. CR Zizhu Business Overview Table 64. CR Zizhu Latanoprost for Chronic Angle Closure Glaucoma Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. CR Zizhu Latanoprost for Chronic Angle Closure Glaucoma Product Portfolio Table 66. CR Zizhu Recent Development Table 67. Novartis Company Information Table 68. Novartis Business Overview Table 69. Novartis Latanoprost for Chronic Angle Closure Glaucoma Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Novartis Latanoprost for Chronic Angle Closure Glaucoma Product Portfolio Table 71. Novartis Recent Development Table 72. Mylan Company Information Table 73. Mylan Business Overview Table 74. Mylan Latanoprost for Chronic Angle Closure Glaucoma Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Mylan Latanoprost for Chronic Angle Closure Glaucoma Product Portfolio Table 76. Mylan Recent Development Table 77. China Medical System Holdings Company Information Table 78. China Medical System Holdings Business Overview Table 79. China Medical System Holdings Latanoprost for Chronic Angle Closure Glaucoma Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. China Medical System Holdings Latanoprost for Chronic Angle Closure Glaucoma Product Portfolio Table 81. China Medical System Holdings Recent Development Table 82. Pfizer Company Information Table 83. Pfizer Business Overview Table 84. Pfizer Latanoprost for Chronic Angle Closure Glaucoma Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Pfizer Latanoprost for Chronic Angle Closure Glaucoma Product Portfolio Table 86. Pfizer Recent Development Table 87. Jiangsu Hengrui Pharmaceuticals Company Information Table 88. Jiangsu Hengrui Pharmaceuticals Business Overview Table 89. Jiangsu Hengrui Pharmaceuticals Latanoprost for Chronic Angle Closure Glaucoma Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Jiangsu Hengrui Pharmaceuticals Latanoprost for Chronic Angle Closure Glaucoma Product Portfolio Table 91. Jiangsu Hengrui Pharmaceuticals Recent Development Table 92. Teva Company Information Table 93. Teva Business Overview Table 94. Teva Latanoprost for Chronic Angle Closure Glaucoma Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. Teva Latanoprost for Chronic Angle Closure Glaucoma Product Portfolio Table 96. Teva Recent Development Table 97. Taj Pharma Company Information Table 98. Taj Pharma Business Overview Table 99. Taj Pharma Latanoprost for Chronic Angle Closure Glaucoma Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 100. Taj Pharma Latanoprost for Chronic Angle Closure Glaucoma Product Portfolio Table 101. Taj Pharma Recent Development Table 102. Apotex Company Information Table 103. Apotex Business Overview Table 104. Apotex Latanoprost for Chronic Angle Closure Glaucoma Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 105. Apotex Latanoprost for Chronic Angle Closure Glaucoma Product Portfolio Table 106. Apotex Recent Development Table 107. Key Raw Materials Table 108. Raw Materials Key Suppliers Table 109. Latanoprost for Chronic Angle Closure Glaucoma Distributors List Table 110. Latanoprost for Chronic Angle Closure Glaucoma Customers List Table 111. Research Programs/Design for This Report Table 112. Authors List of This Report Table 113. Secondary Sources Table 114. Primary Sources List of Figures Figure 1. Latanoprost for Chronic Angle Closure Glaucoma Product Image Figure 2. Global Latanoprost for Chronic Angle Closure Glaucoma Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Latanoprost for Chronic Angle Closure Glaucoma Market Size (2021-2032) & (US$ Million) Figure 4. Global Latanoprost for Chronic Angle Closure Glaucoma Sales (2021-2032) & (K Units) Figure 5. Global Latanoprost for Chronic Angle Closure Glaucoma Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Latanoprost for Chronic Angle Closure Glaucoma Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Brand Drug Image Figure 9. Generic Drug Image Figure 10. Global Latanoprost for Chronic Angle Closure Glaucoma Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 11. Global Latanoprost for Chronic Angle Closure Glaucoma Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Latanoprost for Chronic Angle Closure Glaucoma Sales Market Share by Type (2021-2032) Figure 13. Global Latanoprost for Chronic Angle Closure Glaucoma Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Latanoprost for Chronic Angle Closure Glaucoma Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Latanoprost for Chronic Angle Closure Glaucoma Revenue Market Share by Type (2021-2032) Figure 16. Male Patients Image Figure 17. Female Patients Image Figure 18. Global Latanoprost for Chronic Angle Closure Glaucoma Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 19. Global Latanoprost for Chronic Angle Closure Glaucoma Sales Market Share 2021 VS 2025 VS 2032 Figure 20. Global Latanoprost for Chronic Angle Closure Glaucoma Sales Market Share by Application (2021-2032) Figure 21. Global Latanoprost for Chronic Angle Closure Glaucoma Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Latanoprost for Chronic Angle Closure Glaucoma Revenue Market Share 2021 VS 2025 VS 2032 Figure 23. Global Latanoprost for Chronic Angle Closure Glaucoma Revenue Market Share by Application (2021-2032) Figure 24. North America Latanoprost for Chronic Angle Closure Glaucoma Sales and Growth Rate (2021-2032) & (K Units) Figure 25. North America Latanoprost for Chronic Angle Closure Glaucoma Sales Market Share by Country (2021-2032) Figure 26. U.S. Latanoprost for Chronic Angle Closure Glaucoma Sales and Growth Rate (2021-2032) & (K Units) Figure 27. Canada Latanoprost for Chronic Angle Closure Glaucoma Sales and Growth Rate (2021-2032) & (K Units) Figure 28. Mexico Latanoprost for Chronic Angle Closure Glaucoma Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Europe Latanoprost for Chronic Angle Closure Glaucoma Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Europe Latanoprost for Chronic Angle Closure Glaucoma Sales Market Share by Country (2021-2032) Figure 31. Germany Latanoprost for Chronic Angle Closure Glaucoma Sales and Growth Rate (2021-2032) & (K Units) Figure 32. France Latanoprost for Chronic Angle Closure Glaucoma Sales and Growth Rate (2021-2032) & (K Units) Figure 33. U.K. Latanoprost for Chronic Angle Closure Glaucoma Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Italy Latanoprost for Chronic Angle Closure Glaucoma Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Netherlands Latanoprost for Chronic Angle Closure Glaucoma Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Asia Pacific Latanoprost for Chronic Angle Closure Glaucoma Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Asia Pacific Latanoprost for Chronic Angle Closure Glaucoma Sales Market Share by Country (2021-2032) Figure 38. China Latanoprost for Chronic Angle Closure Glaucoma Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Japan Latanoprost for Chronic Angle Closure Glaucoma Sales and Growth Rate (2021-2032) & (K Units) Figure 40. South Korea Latanoprost for Chronic Angle Closure Glaucoma Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Southeast Asia Latanoprost for Chronic Angle Closure Glaucoma Sales and Growth Rate (2021-2032) & (K Units) Figure 42. India Latanoprost for Chronic Angle Closure Glaucoma Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Australia Latanoprost for Chronic Angle Closure Glaucoma Sales and Growth Rate (2021-2032) & (K Units) Figure 44. South America, Middle East and Africa Latanoprost for Chronic Angle Closure Glaucoma Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South America, Middle East and Africa Latanoprost for Chronic Angle Closure Glaucoma Sales Market Share by Country (2021-2032) Figure 46. Brazil Latanoprost for Chronic Angle Closure Glaucoma Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South Africa Latanoprost for Chronic Angle Closure Glaucoma Sales and Growth Rate (2021-2032) & (K Units) Figure 48. Saudi Arabia Latanoprost for Chronic Angle Closure Glaucoma Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Turkey Latanoprost for Chronic Angle Closure Glaucoma Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Argentina Latanoprost for Chronic Angle Closure Glaucoma Sales and Growth Rate (2021-2032) & (K Units) Figure 51. UAE Latanoprost for Chronic Angle Closure Glaucoma Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Egypt Latanoprost for Chronic Angle Closure Glaucoma Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Chile Latanoprost for Chronic Angle Closure Glaucoma Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Global Latanoprost for Chronic Angle Closure Glaucoma Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 55. Global Latanoprost for Chronic Angle Closure Glaucoma Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 56. North America Latanoprost for Chronic Angle Closure Glaucoma Revenue (2021-2032) & (US$ Million) Figure 57. North America Latanoprost for Chronic Angle Closure Glaucoma Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 58. Europe Latanoprost for Chronic Angle Closure Glaucoma Revenue (2021-2032) & (US$ Million) Figure 59. Europe Latanoprost for Chronic Angle Closure Glaucoma Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Asia-Pacific Latanoprost for Chronic Angle Closure Glaucoma Revenue (2021-2032) & (US$ Million) Figure 61. Asia-Pacific Latanoprost for Chronic Angle Closure Glaucoma Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. South America, Middle East and Africa Latanoprost for Chronic Angle Closure Glaucoma Revenue (2021-2032) & (US$ Million) Figure 63. South America, Middle East and Africa Latanoprost for Chronic Angle Closure Glaucoma Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Latanoprost for Chronic Angle Closure Glaucoma Value Chain Figure 65. Manufacturing Cost Structure Figure 66. Latanoprost for Chronic Angle Closure Glaucoma Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Brand Drug
  • Generic Drug
Applications
  • Male Patients
  • Female Patients
Companies covered
  • CR Zizhu
  • Novartis
  • Mylan
  • China Medical System Holdings
  • Pfizer
  • Jiangsu Hengrui Pharmaceuticals
  • Teva
  • Taj Pharma
  • Apotex

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Latanoprost for Chronic Angle Closure Glaucoma Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Latanoprost for Chronic Angle Closure Glaucoma Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Latanoprost for Chronic Angle Closure Glaucoma Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Latanoprost for Chronic Angle Closure Glaucoma Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Latanoprost for Chronic Angle Closure Glaucoma Market Dynamics
  1. 2.1 Latanoprost for Chronic Angle Closure Glaucoma Industry Trends
  2. 2.2 Latanoprost for Chronic Angle Closure Glaucoma Industry Drivers
  3. 2.3 Latanoprost for Chronic Angle Closure Glaucoma Industry Opportunities and Challenges
  4. 2.4 Latanoprost for Chronic Angle Closure Glaucoma Industry Restraints
3 Latanoprost for Chronic Angle Closure Glaucoma Market by Manufacturers
  1. 3.1 Global Latanoprost for Chronic Angle Closure Glaucoma Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Latanoprost for Chronic Angle Closure Glaucoma Sales by Manufacturers (2021-2026)
  3. 3.3 Global Latanoprost for Chronic Angle Closure Glaucoma Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Latanoprost for Chronic Angle Closure Glaucoma Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Latanoprost for Chronic Angle Closure Glaucoma Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Latanoprost for Chronic Angle Closure Glaucoma Manufacturers, Product Type & Application
  7. 3.7 Global Latanoprost for Chronic Angle Closure Glaucoma Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Latanoprost for Chronic Angle Closure Glaucoma Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Latanoprost for Chronic Angle Closure Glaucoma Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Latanoprost for Chronic Angle Closure Glaucoma Tier 1, Tier 2, and Tier 3
4 Latanoprost for Chronic Angle Closure Glaucoma Market by Type
  1. 4.1 Latanoprost for Chronic Angle Closure Glaucoma Type Introduction
  2. 4.1.1 Brand Drug
  3. 4.1.2 Generic Drug
  4. 4.2 Global Latanoprost for Chronic Angle Closure Glaucoma Sales by Type
  5. 4.2.1 Global Latanoprost for Chronic Angle Closure Glaucoma Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Latanoprost for Chronic Angle Closure Glaucoma Sales by Type (2021-2032)
  7. 4.2.3 Global Latanoprost for Chronic Angle Closure Glaucoma Sales Market Share by Type (2021-2032)
  8. 4.3 Global Latanoprost for Chronic Angle Closure Glaucoma Revenue by Type
  9. 4.3.1 Global Latanoprost for Chronic Angle Closure Glaucoma Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Latanoprost for Chronic Angle Closure Glaucoma Revenue by Type (2021-2032)
  11. 4.3.3 Global Latanoprost for Chronic Angle Closure Glaucoma Revenue Market Share by Type (2021-2032)
5 Latanoprost for Chronic Angle Closure Glaucoma Market by Application
  1. 5.1 Latanoprost for Chronic Angle Closure Glaucoma Application Introduction
  2. 5.1.1 Male Patients
  3. 5.1.2 Female Patients
  4. 5.2 Global Latanoprost for Chronic Angle Closure Glaucoma Sales by Application
  5. 5.2.1 Global Latanoprost for Chronic Angle Closure Glaucoma Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Latanoprost for Chronic Angle Closure Glaucoma Sales by Application (2021-2032)
  7. 5.2.3 Global Latanoprost for Chronic Angle Closure Glaucoma Sales Market Share by Application (2021-2032)
  8. 5.3 Global Latanoprost for Chronic Angle Closure Glaucoma Revenue by Application
  9. 5.3.1 Global Latanoprost for Chronic Angle Closure Glaucoma Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Latanoprost for Chronic Angle Closure Glaucoma Revenue by Application (2021-2032)
  11. 5.3.3 Global Latanoprost for Chronic Angle Closure Glaucoma Revenue Market Share by Application (2021-2032)
6 Global Latanoprost for Chronic Angle Closure Glaucoma Sales by Region
  1. 6.1 Global Latanoprost for Chronic Angle Closure Glaucoma Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Latanoprost for Chronic Angle Closure Glaucoma Sales by Region (2021-2032)
  3. 6.2.1 Global Latanoprost for Chronic Angle Closure Glaucoma Sales by Region (2021-2026)
  4. 6.2.2 Global Latanoprost for Chronic Angle Closure Glaucoma Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Latanoprost for Chronic Angle Closure Glaucoma Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Latanoprost for Chronic Angle Closure Glaucoma Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Latanoprost for Chronic Angle Closure Glaucoma Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Latanoprost for Chronic Angle Closure Glaucoma Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Latanoprost for Chronic Angle Closure Glaucoma Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Latanoprost for Chronic Angle Closure Glaucoma Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Latanoprost for Chronic Angle Closure Glaucoma Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Latanoprost for Chronic Angle Closure Glaucoma Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Latanoprost for Chronic Angle Closure Glaucoma Revenue by Region
  1. 7.1 Global Latanoprost for Chronic Angle Closure Glaucoma Revenue by Region
  2. 7.1.1 Global Latanoprost for Chronic Angle Closure Glaucoma Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Latanoprost for Chronic Angle Closure Glaucoma Revenue by Region (2021-2026)
  4. 7.1.3 Global Latanoprost for Chronic Angle Closure Glaucoma Revenue by Region (2027-2032)
  5. 7.1.4 Global Latanoprost for Chronic Angle Closure Glaucoma Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Latanoprost for Chronic Angle Closure Glaucoma Revenue (2021-2032)
  8. 7.2.2 North America Latanoprost for Chronic Angle Closure Glaucoma Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Latanoprost for Chronic Angle Closure Glaucoma Revenue (2021-2032)
  11. 7.3.2 Europe Latanoprost for Chronic Angle Closure Glaucoma Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Latanoprost for Chronic Angle Closure Glaucoma Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Latanoprost for Chronic Angle Closure Glaucoma Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Latanoprost for Chronic Angle Closure Glaucoma Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Latanoprost for Chronic Angle Closure Glaucoma Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 CR Zizhu
  2. 8.1.1 CR Zizhu Company Information
  3. 8.1.2 CR Zizhu Business Overview
  4. 8.1.3 CR Zizhu Latanoprost for Chronic Angle Closure Glaucoma Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 CR Zizhu Latanoprost for Chronic Angle Closure Glaucoma Product Portfolio
  6. 8.1.5 CR Zizhu Recent Developments
  7. 8.2 Novartis
  8. 8.2.1 Novartis Company Information
  9. 8.2.2 Novartis Business Overview
  10. 8.2.3 Novartis Latanoprost for Chronic Angle Closure Glaucoma Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Novartis Latanoprost for Chronic Angle Closure Glaucoma Product Portfolio
  12. 8.2.5 Novartis Recent Developments
  13. 8.3 Mylan
  14. 8.3.1 Mylan Company Information
  15. 8.3.2 Mylan Business Overview
  16. 8.3.3 Mylan Latanoprost for Chronic Angle Closure Glaucoma Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Mylan Latanoprost for Chronic Angle Closure Glaucoma Product Portfolio
  18. 8.3.5 Mylan Recent Developments
  19. 8.4 China Medical System Holdings
  20. 8.4.1 China Medical System Holdings Company Information
  21. 8.4.2 China Medical System Holdings Business Overview
  22. 8.4.3 China Medical System Holdings Latanoprost for Chronic Angle Closure Glaucoma Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 China Medical System Holdings Latanoprost for Chronic Angle Closure Glaucoma Product Portfolio
  24. 8.4.5 China Medical System Holdings Recent Developments
  25. 8.5 Pfizer
  26. 8.5.1 Pfizer Company Information
  27. 8.5.2 Pfizer Business Overview
  28. 8.5.3 Pfizer Latanoprost for Chronic Angle Closure Glaucoma Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Pfizer Latanoprost for Chronic Angle Closure Glaucoma Product Portfolio
  30. 8.5.5 Pfizer Recent Developments
  31. 8.6 Jiangsu Hengrui Pharmaceuticals
  32. 8.6.1 Jiangsu Hengrui Pharmaceuticals Company Information
  33. 8.6.2 Jiangsu Hengrui Pharmaceuticals Business Overview
  34. 8.6.3 Jiangsu Hengrui Pharmaceuticals Latanoprost for Chronic Angle Closure Glaucoma Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Jiangsu Hengrui Pharmaceuticals Latanoprost for Chronic Angle Closure Glaucoma Product Portfolio
  36. 8.6.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
  37. 8.7 Teva
  38. 8.7.1 Teva Company Information
  39. 8.7.2 Teva Business Overview
  40. 8.7.3 Teva Latanoprost for Chronic Angle Closure Glaucoma Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Teva Latanoprost for Chronic Angle Closure Glaucoma Product Portfolio
  42. 8.7.5 Teva Recent Developments
  43. 8.8 Taj Pharma
  44. 8.8.1 Taj Pharma Company Information
  45. 8.8.2 Taj Pharma Business Overview
  46. 8.8.3 Taj Pharma Latanoprost for Chronic Angle Closure Glaucoma Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Taj Pharma Latanoprost for Chronic Angle Closure Glaucoma Product Portfolio
  48. 8.8.5 Taj Pharma Recent Developments
  49. 8.9 Apotex
  50. 8.9.1 Apotex Company Information
  51. 8.9.2 Apotex Business Overview
  52. 8.9.3 Apotex Latanoprost for Chronic Angle Closure Glaucoma Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Apotex Latanoprost for Chronic Angle Closure Glaucoma Product Portfolio
  54. 8.9.5 Apotex Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Latanoprost for Chronic Angle Closure Glaucoma Value Chain Analysis
  2. 9.1.1 Latanoprost for Chronic Angle Closure Glaucoma Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Latanoprost for Chronic Angle Closure Glaucoma Production Mode & Process
  6. 9.2 Latanoprost for Chronic Angle Closure Glaucoma Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Latanoprost for Chronic Angle Closure Glaucoma Distributors
  9. 9.2.3 Latanoprost for Chronic Angle Closure Glaucoma Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst